[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07519772":3,"trial-entities:NCT07519772":549,"trial-summary:NCT07519772":554},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":22,"study_type":23,"primary_purpose":24,"phases":25,"enrollment_info":28,"interventions":31,"primary_outcomes":43,"secondary_outcomes":59,"sex":85,"minimum_age":86,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":87,"std_ages":114,"locations":117,"central_contacts":532,"overall_officials":537,"references":541,"see_also_links":542},"NCT07519772","1045-008","A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","A Phase 1b\u002F2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma","RECRUITING","2031-04-01","2026-09","2026-09-17","2026-05-03","Merck Sharp & Dohme LLC","INDUSTRY",false,"Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system.\n\nIn this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer.\n\nThe goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.",null,[19,20,21],"Lymphoma, Non-Hodgkin","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse",[],"INTERVENTIONAL","TREATMENT",[26,27],"PHASE1","PHASE2",{"count":29,"type":30},280,"ESTIMATED",[32],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":41},"BIOLOGICAL","MK-1045","Intravenous (IV) Infusion or Subcutaneous (SC) injection",[37,38,39,40],"Arm 1: Follicular Lymphoma (FL) MK-1045 Monotherapy Dose Optimization","Arm 2: FL MK-1045 Longer Dosing Interval","Arm 3: FL MK-1045 Subcutaneous Administration","Arm 4: Diffuse Large B-cell Lymphoma (DLBCL) MK-1045 Monotherapy Dose Optimization",[42],"CN-201",[44,48,52,56],{"measure":45,"description":46,"timeFrame":47},"Number of Participants Who Experience an Adverse Event (AE)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be reported.","Up to approximately 49 months",{"measure":49,"description":50,"timeFrame":51},"Number of Participants Who Discontinue Study Treatment Due to an AE","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.","Up to approximately 12 months",{"measure":53,"description":54,"timeFrame":55},"Arms 2 and 3: Number of Participants Who Experience Dose Limiting Toxicity (DLT)","DLT will be defined as any drug-related AE observed during the DLT evaluation period (up to 28 days) that results in a change to a given dose or a delay in initiating the next treatment.","Up to approximately 28 days",{"measure":57,"description":58,"timeFrame":47},"Arms 1, 2, and 4: Objective Response Rate (ORR) per Lugano Response Criteria as assessed by Blinded Independent Central review (BICR)","ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and will be evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. Response will be assessed based on the International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no\u002Fminimal fluorodeoxyglucose \\[FDG\\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate\u002Fhigh FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \\>50% in length beyond normal). In Arms 1, 2, and 4, the percentage of participants who experience CR or PR as assessed by BICR will be presented.",[60,63,66,70,73,76,79,82],{"measure":61,"description":62,"timeFrame":47},"Arms 1, 2, and 4: Duration of Response (DOR) per Lugano Response Criteria as assessed by BICR","For participants who demonstrate a confirmed complete response (CR) or partial response (PR), DOR is defined as the time from CR or PR to documented disease progression or death. Participants are assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response will be evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no\u002Fminimal fluorodeoxyglucose \\[FDG\\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate\u002Fhigh FDG uptake) and radiologic response (≥50% decrease in sum of product diameters (SPD) for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \\>50% in length beyond normal). DOR as assessed by BICR will be presented for Arms 1, 2, and 4.",{"measure":64,"description":65,"timeFrame":47},"Arm 3: DOR per Lugano Response Criteria as assessed by Investigator","For participants who demonstrate a confirmed complete response (CR) or partial response (PR), DOR is defined as the time from CR or PR to documented disease progression or death. Participants are assessed using computed tomography (CT) and positron emission tomography (PET)-CT and response will be evaluated based on the Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no\u002Fminimal fluorodeoxyglucose \\[FDG\\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate\u002Fhigh FDG uptake) and radiologic response (≥50% decrease in sum of product diameters (SPD) for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \\>50% in length beyond normal). DOR as assessed by the Investigator will be presented for Arm 3.",{"measure":67,"description":68,"timeFrame":69},"Area Under the Concentration-time Curve Measured at Steady State (AUCss) of MK-1045","Blood samples will be collected to determine the AUCss of MK-1045 in plasma.","Pre-dose and at designated time points post-dose up to 12 months",{"measure":71,"description":72,"timeFrame":69},"Trough Concentration (Ctrough) of MK-1045","Blood samples will be collected to determine the Ctrough of MK-1045 in plasma.",{"measure":74,"description":75,"timeFrame":69},"Maximum Serum Concentration (Cmax) of MK-1045","Blood samples will be collected to determine the Cmax of MK-1045 in plasma.",{"measure":77,"description":78,"timeFrame":69},"Arms 1, 2, and 4: Time to Maximum Serum Concentration (Tmax) of MK-1045","Blood samples will be collected to determine the Tmax of MK-1045 in plasma.",{"measure":80,"description":81,"timeFrame":69},"Arm 3: Absolute Bioavailability Expressed as a Percentage (F%) of MK-1045","Blood samples will be collected to determine the F% of MK-1045 in plasma.",{"measure":83,"description":84,"timeFrame":47},"Arm 3: ORR per Lugano Response Criteria as assessed by Investigator","ORR is defined as the percentage of the participants who had complete response (CR) or partial response (PR) and will be evaluated using computed tomography (CT) and positron emission tomography (PET)-CT. Response will be assessed based on the International Working Group Criteria: Lugano Classification (Cheson et al, Journal of Clinical Oncology, 2014). CR is complete metabolic (no\u002Fminimal fluorodeoxyglucose \\[FDG\\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions. PR is partial metabolic (moderate\u002Fhigh FDG uptake) and radiologic response (≥50% decrease in sum of product diameters for multiple lesions of up to 6 target measurable nodes and extranodal sites, no increase in lesions, and spleen regressed by \\>50% in length beyond normal). In Arm 3, the percentage of participants who experience CR or PR as assessed by the Investigator will be presented.","ALL","18 Years",{"inclusion":88,"exclusion":98,"raw_text":113},[89,90,91,92,93,94,95,96,97],"Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.","Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).","DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.","Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).","Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.","Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.","Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.","Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.","Has radiographically measurable disease per Lugano Response Criteria.",[99,100,101,102,103,104,105,106,107,108,109,110,111,112],"Has received a solid organ transplant.","Had or has clinically relevant central nervous system (CNS) diseases.","Has a history of serious cardiovascular or cerebrovascular diseases.","Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.","Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.","Has received a live or live-attenuated vaccine within 30 days of randomization.","Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.","Has a known additional malignancy that is progressing or required active treatment within the past 2 years.","Has known active CNS lymphoma or involvement.","Has active autoimmune disease that required systemic treatment in the past 2 years.","Has active infection requiring systemic therapy.","Has a history of severe bleeding disorders.","Has not recovered from major surgery or has ongoing surgical complications.","Has diagnosis of primary mediastinal B-cell lymphoma.","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.\n* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).\n* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.\n* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).\n* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.\n* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.\n* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.\n* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.\n* Has radiographically measurable disease per Lugano Response Criteria.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has received a solid organ transplant.\n* Had or has clinically relevant central nervous system (CNS) diseases.\n* Has a history of serious cardiovascular or cerebrovascular diseases.\n* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days of randomization.\n* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.\n* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.\n* Has known active CNS lymphoma or involvement.\n* Has active autoimmune disease that required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has a history of severe bleeding disorders.\n* Has not recovered from major surgery or has ongoing surgical complications.\n* Has diagnosis of primary mediastinal B-cell lymphoma.",[115,116],"ADULT","OLDER_ADULT",[118,132,143,152,162,173,180,192,203,215,227,239,250,261,273,284,294,301,311,321,330,341,351,361,373,384,395,406,413,425,436,445,455,462,473,483,493,500,510,522],{"facility":119,"status":8,"city":120,"state":121,"zip":122,"country":123,"contacts":124,"geoPoint":129},"Colorado Blood Cancer Institute ( Site 7000)","Denver","Colorado","80218","United States",[125],{"name":126,"role":127,"phone":128},"Study Coordinator","CONTACT","720-748-4800",{"lat":130,"lon":131},39.73915,-104.9847,{"facility":133,"status":8,"city":134,"state":135,"zip":136,"country":123,"contacts":137,"geoPoint":140},"SCRI Oncology Partners ( Site 0100)","Nashville","Tennessee","37203",[138],{"name":126,"role":127,"phone":139},"844-482-4812",{"lat":141,"lon":142},36.16589,-86.78444,{"facility":144,"status":8,"city":145,"state":146,"zip":147,"country":148,"contacts":149},"Instituto Alexander Fleming ( Site 1404)","Ciudad Autonoma de Buenos Aires","Buenos Aires","C1426ANZ","Argentina",[150],{"name":126,"role":127,"phone":151},"+541132218900",{"facility":153,"status":8,"city":154,"state":146,"zip":155,"country":148,"contacts":156,"geoPoint":159},"Hospital Universitario Austral ( Site 1402)","Pilar","B1629AHJ",[157],{"name":126,"role":127,"phone":158},"+54 (0230) 438-8888",{"lat":160,"lon":161},-34.45867,-58.91398,{"facility":163,"status":8,"city":164,"state":165,"zip":166,"country":148,"contacts":167,"geoPoint":170},"Sanatorio Nuestra Senora del Rosario ( Site 1403)","Rosario","Santa Fe Province","2001",[168],{"name":126,"role":127,"phone":169},"+5493416149225",{"lat":171,"lon":172},-32.94682,-60.63932,{"facility":174,"status":8,"city":175,"zip":176,"country":148,"contacts":177},"Hospital Aleman ( Site 1400)","CABA","C1118AAT",[178],{"name":126,"role":127,"phone":179},"+541148277000",{"facility":181,"status":8,"city":182,"state":183,"zip":184,"country":185,"contacts":186,"geoPoint":189},"Townsville University Hospital ( Site 0204)","Townsville","Queensland","4814","Australia",[187],{"name":126,"role":127,"phone":188},"0744331111",{"lat":190,"lon":191},-19.26639,146.80569,{"facility":193,"status":8,"city":194,"state":195,"zip":196,"country":185,"contacts":197,"geoPoint":200},"Box Hill Hospital ( Site 0202)","Box Hill","Victoria","3128",[198],{"name":126,"role":127,"phone":199},"+611300342255",{"lat":201,"lon":202},-37.81887,145.12545,{"facility":204,"status":8,"city":205,"state":206,"zip":207,"country":208,"contacts":209,"geoPoint":212},"Princess Margaret Cancer Centre ( Site 0301)","Toronto","Ontario","M5G 2M9","Canada",[210],{"name":126,"role":127,"phone":211},"416-946-4558",{"lat":213,"lon":214},43.70643,-79.39864,{"facility":216,"status":8,"city":217,"state":218,"zip":219,"country":220,"contacts":221,"geoPoint":224},"Clínica Alemana de Santiago ( Site 1608)","Santiago","Region M. de Santiago","7650568","Chile",[222],{"name":126,"role":127,"phone":223},"56222101111 ext 6218",{"lat":225,"lon":226},-33.45694,-70.64827,{"facility":228,"status":8,"city":229,"state":230,"zip":231,"country":232,"contacts":233,"geoPoint":236},"Beijing Cancer hospital ( Site 1701)","Beijing","Beijing Municipality","100142","China",[234],{"name":126,"role":127,"phone":235},"+86 010-88196922",{"lat":237,"lon":238},39.9075,116.39723,{"facility":240,"status":8,"city":241,"state":242,"zip":243,"country":232,"contacts":244,"geoPoint":247},"Sun Yat-Sen University Cancer Center ( Site 1712)","Guangzhou","Guangdong","510060",[245],{"name":126,"role":127,"phone":246},"+8602087343349",{"lat":248,"lon":249},23.11667,113.25,{"facility":251,"status":8,"city":252,"state":253,"zip":254,"country":232,"contacts":255,"geoPoint":258},"Fudan University Shanghai Cancer Center ( Site 1711)","Shanghai","Shanghai Municipality","200032",[256],{"name":126,"role":127,"phone":257},"8602138196379",{"lat":259,"lon":260},31.22222,121.45806,{"facility":262,"status":8,"city":263,"state":264,"zip":265,"country":266,"contacts":267,"geoPoint":270},"UKGM Gießen\u002FMarburg ( Site 0505)","Giessen","Hesse","35392","Germany",[268],{"name":126,"role":127,"phone":269},"+49 64198542651",{"lat":271,"lon":272},50.58727,8.67554,{"facility":274,"status":8,"city":275,"zip":276,"country":277,"contacts":278,"geoPoint":281},"Carmel Hospital ( Site 0602)","Haifa","3436212","Israel",[279],{"name":126,"role":127,"phone":280},"+97248250211",{"lat":282,"lon":283},32.81303,34.99928,{"facility":285,"status":8,"city":286,"zip":287,"country":277,"contacts":288,"geoPoint":291},"Shaare Zedek Medical Center ( Site 0603)","Jerusalem","9103102",[289],{"name":126,"role":127,"phone":290},"+972544922952",{"lat":292,"lon":293},31.76904,35.21633,{"facility":295,"status":8,"city":286,"zip":296,"country":277,"contacts":297,"geoPoint":300},"Haddasah Medical Center ( Site 0600)","9112001",[298],{"name":126,"role":127,"phone":299},"+972539101736",{"lat":292,"lon":293},{"facility":302,"status":8,"city":303,"zip":304,"country":277,"contacts":305,"geoPoint":308},"Sheba Medical Center ( Site 0601)","Ramat Gan","5265601",[306],{"name":126,"role":127,"phone":307},"97235303030",{"lat":309,"lon":310},32.08227,34.81065,{"facility":312,"status":8,"city":313,"zip":314,"country":277,"contacts":315,"geoPoint":318},"Sourasky Medical Center. ( Site 0604)","Tel Aviv","6423906",[316],{"name":126,"role":127,"phone":317},"+97236974444",{"lat":319,"lon":320},32.08088,34.78057,{"facility":322,"status":8,"city":323,"state":324,"zip":325,"country":326,"contacts":327},"Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Ematologia Oncologica ( Site 0700)","Campania","Napoli","80131","Italy",[328],{"name":126,"role":127,"phone":329},"00390815903382",{"facility":331,"status":8,"city":332,"state":333,"zip":334,"country":326,"contacts":335,"geoPoint":338},"INOC - Istituto Nazionale Oncologico Candiolo ( Site 0701)","Candiolo","Piedmont","10060",[336],{"name":126,"role":127,"phone":337},"+390119933355",{"lat":339,"lon":340},44.95858,7.59812,{"facility":342,"status":8,"city":343,"zip":344,"country":326,"contacts":345,"geoPoint":348},"Istituto Europeo di Oncologia IRCCS ( Site 0702)","Milan","20141",[346],{"name":126,"role":127,"phone":347},"0039 02 57489403",{"lat":349,"lon":350},42.78235,12.59836,{"facility":352,"status":8,"city":353,"zip":354,"country":326,"contacts":355,"geoPoint":358},"Fondazione Policlinico Universitario Agostino Gemelli ( Site 0705)","Roma","00168",[356],{"name":126,"role":127,"phone":357},"00390630154180",{"lat":359,"lon":360},44.99364,11.10642,{"facility":362,"status":8,"city":363,"state":364,"zip":365,"country":366,"contacts":367,"geoPoint":370},"Pratia MCM Krakow ( Site 0903)","Krakow","Lesser Poland Voivodeship","30-727","Poland",[368],{"name":126,"role":127,"phone":369},"+48122958160",{"lat":371,"lon":372},50.06143,19.93658,{"facility":374,"status":8,"city":375,"state":376,"zip":377,"country":366,"contacts":378,"geoPoint":381},"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900)","Warsaw","Masovian Voivodeship","02-781",[379],{"name":126,"role":127,"phone":380},"+48225462000",{"lat":382,"lon":383},52.22977,21.01178,{"facility":385,"status":8,"city":386,"state":387,"zip":388,"country":366,"contacts":389,"geoPoint":392},"Pratia Onkologia Katowice ( Site 0902)","Katowice","Silesian Voivodeship","40-519",[390],{"name":126,"role":127,"phone":391},"+48501714019",{"lat":393,"lon":394},50.2597,19.02173,{"facility":396,"status":8,"city":397,"zip":398,"country":399,"contacts":400,"geoPoint":403},"Seoul National University Hospital ( Site 0800)","Seoul","03080","South Korea",[401],{"name":126,"role":127,"phone":402},"+82220722228",{"lat":404,"lon":405},37.566,126.9784,{"facility":407,"status":8,"city":397,"zip":408,"country":399,"contacts":409,"geoPoint":412},"The Catholic University of Korea, Yeouido St. Mary's Hospital ( Site 0801)","07345",[410],{"name":126,"role":127,"phone":411},"+82237791049",{"lat":404,"lon":405},{"facility":414,"status":8,"city":415,"state":416,"zip":417,"country":418,"contacts":419,"geoPoint":422},"Institut Català d'Oncologia (ICO) - Badalona ( Site 1103)","Badalona","Barcelona","08916","Spain",[420],{"name":126,"role":127,"phone":421},"34934978387",{"lat":423,"lon":424},41.45004,2.24741,{"facility":426,"status":8,"city":427,"state":428,"zip":429,"country":418,"contacts":430,"geoPoint":433},"Hospital Virgen de la Victoria ( Site 1104)","Málaga","Malaga","29010",[431],{"name":126,"role":127,"phone":432},"34951032508",{"lat":434,"lon":435},36.72016,-4.42034,{"facility":437,"status":8,"city":416,"zip":438,"country":418,"contacts":439,"geoPoint":442},"Hospital Universitari Vall de Hebron ( Site 1102)","08035",[440],{"name":126,"role":127,"phone":441},"+34 932746000",{"lat":443,"lon":444},41.38879,2.15899,{"facility":446,"status":8,"city":447,"zip":448,"country":418,"contacts":449,"geoPoint":452},"Hospital Universitario Gregorio Maranon ( Site 1101)","Madrid","28007",[450],{"name":126,"role":127,"phone":451},"+34915868888",{"lat":453,"lon":454},40.4165,-3.70256,{"facility":456,"status":8,"city":447,"zip":457,"country":418,"contacts":458,"geoPoint":461},"Hospital Universitario 12 de Octubre ( Site 1105)","28041",[459],{"name":126,"role":127,"phone":460},"+34917792809",{"lat":453,"lon":454},{"facility":463,"status":8,"city":464,"zip":465,"country":466,"contacts":467,"geoPoint":470},"Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 1000)","Ankara","06230","Turkey (Türkiye)",[468],{"name":126,"role":127,"phone":469},"+903123052941",{"lat":471,"lon":472},39.91987,32.85427,{"facility":474,"status":8,"city":475,"zip":476,"country":466,"contacts":477,"geoPoint":480},"Antalya Egitim ve Arastirma Hastanesi ( Site 1003)","Antalya","7100",[478],{"name":126,"role":127,"phone":479},"+905315269050",{"lat":481,"lon":482},36.90812,30.69556,{"facility":484,"status":8,"city":485,"zip":486,"country":466,"contacts":487,"geoPoint":490},"Koç Üniversitesi Hastanesi ( Site 1001)","Istanbul","34010",[488],{"name":126,"role":127,"phone":489},"02124678700",{"lat":491,"lon":492},41.01384,28.94966,{"facility":494,"status":8,"city":485,"zip":495,"country":466,"contacts":496,"geoPoint":499},"Medipol Mega Universite Hastanesi ( Site 1002)","34214",[497],{"name":126,"role":127,"phone":498},"+905426202524",{"lat":491,"lon":492},{"facility":501,"status":8,"city":502,"zip":503,"country":466,"contacts":504,"geoPoint":507},"Samsun Ondokuz Mayis Universitesi Tip Fakultesi Hastanesi ( Site 1005)","Samsun","55270",[505],{"name":126,"role":127,"phone":506},"+905442398796",{"lat":508,"lon":509},41.27976,36.3361,{"facility":511,"status":8,"city":512,"state":513,"zip":514,"country":515,"contacts":516,"geoPoint":519},"Derriford Hospital ( Site 1304)","Plymouth","Devon","Pl6 8DH","United Kingdom",[517],{"name":126,"role":127,"phone":518},"+441752431043",{"lat":520,"lon":521},50.37153,-4.14305,{"facility":523,"status":8,"city":524,"zip":525,"country":515,"contacts":526,"geoPoint":529},"The Christie NHS Foundation Trust ( Site 1300)","Manchester","M20 4BX",[527],{"name":126,"role":127,"phone":528},"+4401614468201",{"lat":530,"lon":531},53.48095,-2.23743,[533],{"name":534,"role":127,"phone":535,"email":536},"Toll Free Number","1-888-577-8839","Trialsites@msd.com",[538],{"name":539,"affiliation":13,"role":540},"Medical Director","STUDY_DIRECTOR",[],[543,546],{"label":544,"url":545},"Merck Clinical Trials Information","https:\u002F\u002Fwww.merckclinicaltrials.com\u002F",{"label":547,"url":548},"Plain Language Summary","https:\u002F\u002Fwww.trialsummaries.com\u002FStudy\u002FStudyDetails?id=27328&tenant=MT_MSD_9011",{"nct_id":4,"conditions":550,"biomarkers":553},[551,552],"Diffuse Large B-Cell Lymphoma","Follicular Lymphoma",[],{"nct_id":4,"found":555,"summary":556,"prompt_version":566},true,{"design":557,"status":558,"heading":559,"summary":560,"follow_up":561,"word_count":562,"commitments":563,"compensation":564,"drugs_mentioned":565},"This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 200 participants.","completed","A Study of MK-1045 for Non-Hodgkin Lymphoma","This study is testing a new treatment called MK-1045 for two types of non-Hodgkin lymphoma (NHL): follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). NHL is a cancer of the immune system. MK-1045 is an immunotherapy, meaning it helps your immune system fight cancer. Researchers want to see how safe MK-1045 is, how well people tolerate it, and if it can make the cancer shrink or go away. You may be able to join if you are 18 or older, have FL or DLBCL that has come back or not responded to at least two previous treatments. The study aims to enroll about 200 participants. The current status of the study is unclear.","Participants will be monitored for adverse events for up to approximately 44 months, and for treatment discontinuation due to adverse events for up to approximately 12 months.",114,"Not specified in the trial record.","Not stated in the trial record.",[34],"v2"]